Biotricity, Inc. (BTCY) Stock Forecast
BTCY analyst forecast
as of October 21, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +7,900.0% from the latest close
- Next earnings
- —
- 52-week range
- $0.04 – $0.65
BTCY analyst ratings
1 analystsNumber of analysts at each rating.
BTCY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BTCY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $0.00 | $0.00 | $0.00 | −$0.32 | — | — |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BTCY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $0 | $0 | $0 | — | — |
BTCY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BTCY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (FY2027) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BTCY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BTCY beat in 8 of 9.
What analysts expect from BTCY
1 analysts cover Biotricity; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 7,900.0% above the latest close of $0.05. For FY2027 the average estimate is $0.00 per share. Biotricity beat the EPS estimate in 8 of the last 9 quarters.
Related: BTCY income statement, BTCY key metrics, BTCY chart. See the BTCY stock overview for the latest quote and news.
BTCY forecast FAQ
What is Biotricity's price target?
The average analyst price target for Biotricity is $4.00, 7,900.0% above the latest close of $0.05.
Is Biotricity a buy, hold or sell?
Of 1 analysts covering Biotricity, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
Does Biotricity usually beat earnings estimates?
Biotricity reported EPS at or above the analyst estimate in 8 of the last 9 quarters.